Table 1.
Baseline Characteristics (for 137 participants who completed the 12-week intervention)
| Metric | SOC (n=67) | TRE (n=70) | All (n=137) |
|---|---|---|---|
| Age, mean (SD), years | 39.61 (9.39) | 41.07 (8.71) | 40.36 (90.4) |
| Male, n, (%) | 65 (97%) | 60 (84%) | 125 (91%) |
| Female, n, (%) | 2 (3%) | 10 (15%) | 12 (9%) |
| Race, n, (%) | |||
| White | 42 (63%) | 40 (60%) | 82 (60%) |
| Black | 2 (3%) | 3 (4%) | 5 (4%) |
| Asian | 2 (3%) | 3 (4%) | 5 (4%) |
| Hispanic | 9 (13%) | 12 (17%) | 21 (15%) |
| Mixed Race | 2 (3%) | 0 (0%) | 2 (1%) |
| Unknown Race | 10 (15%) | 12 (17%) | 22 (16%) |
| Outcome Measures | |||
| 95% eating window, mean (SD), hours | 13.98 (1.79) | 14.19 (1.39) | 14.09 (1.60) |
| Fasting Glucose, mean (SD), mg/dL | 92.51 (7.45) | 92.31 (7.96) | 92.41 (7.69) |
| HbA1c, mean (SD), % | 5.28 (0.31) | 5.30 (0.40) | 5.29 (0.36) |
| HOMA-IR, mean (SD) | 1.09 (0.71) | 1.13 (0.78) | 1.11 (0.74) |
| Fasting Insulin, mean (SD), mIU/L | 4.70 (2.87) | 4.90 (3.13) | 4.80 (3.00) |
| Prevalence of Cardiometabolic Risk Factors | |||
| BMI ≥ 30 kg/m2, n (%) | 16 (24%) | 20 (29%) | 36 (26%) |
| Fasting Glucose ≥ 100 mg/dL, n (%) | 11 (16%) | 10 (14%) | 21 (15%) |
| HbA1c ≥ 5.7 %, n (%) | 7 (10%) | 7 (10%) | 14 (10%) |
| LDL Cholesterol ≥ 130 mg/dL, n (%) | 25 (37%) | 25 (36%) | 50 (36%) |
| Triglycerides ≥ 150 mg/dL, n (%) | 9 (13%) | 8 (11%) | 17 (12%) |
| HDL Cholesterol <40 mg/dL for males, <50 mg/dL for females, n (%) | 3 (4%) | 6 (9%) | 9 (7%) |
| Systolic Blood Pressure ≥ 135 mmHg, n (%) | 9 (13%) | 16 (23%) | 25 (18%) |
| Diastolic Blood Pressure ≥ 85 mmHg, n (%) | 6 (9%) | 9 (13%) | 15 (11%) |
| CRP ≥ 2.0 mg/dL, n (%) | 12 (18%) | 15 (21%) | 27 (20%) |
| Medications: Type (Drug Names) | |||
| Antihypertensive (Losartan, Olmesartan, Lisinopril, Lisinopril-Hydrochlorothiazide, Atenolol, Metoprolol, Atenolol, Timolol), n (%) | 5 (7%) | 6 (9%) | 11 (8%) |
| Statin, (Crestor, Atorvastatin), n (%) | 4 (6%) | 5 (7%) | 9 (7%) |
| Ezetimibe (Zetia), n (%) | 0 (0%) | 1 (1%) | 1 (1%) |
| Omegas (Omega-3, Fish Oil, Omega-6), n (%) | 14 (21%) | 18 (26%) | 32 (23%) |
| Antidiabetic (Metformin, Jardiance), n (%) | 0 | 2 (3%) | 2 (1%) |
| Melatonin, n (%) | 1 (1%) | 6 (9%) | 7 (5%) |
| Prescription Sleep aid (Ambien), n (%) | 1 (1%) | 0 | 1 (1%) |